Karen’s story

I have an aggressive stage IV melanoma skin cancer which has metastasised to my lungs, bones, liver and lymph glands. I was facing my last Christmas with my young children in late 2013.

I have three children – 6, 12 and 14 years old.

In January 2012 I had a mole removed and was told I had ‘clear margins’. I had one follow up but was really not aware of my increased risk of further disease and what the follow-ups were looking for.

In February 2013 I discovered a lump under my right arm and was diagnosed with stage III melanoma. It was at this point my life turned upside down. I stopped working but I had hope that the surgery would remove all the cancer.

I had my lymph nodes removed and required a permanent medical draining device over the next 3 months. During this time I also recieved adjuvant radiotherapy, the burning of which added to the pain and swelling in my arm that I experienced post surgery (not uncommon for melanoma patients who have had lymph nodes removed from the underarm or groin) and have worn a compression sleeve every day since. My cousin and other friends drove me to my daily radiotherapy and to my appointments with the surgeon. Over those 3 months I entered a world I did not know existed. My vocabulary increased to include all the new words and phrases to describe my illness and treatment.

I suffered cellulitis and, as a result, became aware of the Lymphoedema Association of South Australia. This swelling and the effect of radiotherapy has impacted my arm function and as a result I attended a physiotherapist Lymphoedema & Laser Therapy fortnightly and now monthly.

In May 2013 I was told that the disease had spread further and was unresectable. I was stage IV, and while chemotherapy was an option, success rates were variable. I was ineligible for a clinical trial underway at that time due to my specific tumour gene expression. I was told that if chemotherapy did not work I would not have any more options.

I focussed on my health, green juicing, an alkaline diet, supplements, yoga and long walks every day with friends who formed a roster. I was probably the healthiest I had ever been.

I was beside myself, what do I tell the children, how do I deal with this? I could not stop crying when I thought about my children and the impact this could have on them. The staff at the Southern Adelaide Palliative Services were incredible, I was able to access counselling there where I could talk about issues I couldn’t discuss with anyone else. It was through this group that I discovered another one of my silver linings, the Daw House Complementary Care Centre where I received (and still do receive) support, understanding and spiritual strength.

Chemotherapy did not work and Yervoy was not yet available on PBS. I couldn’t accept this; I had three little boys to help grow up.

My doctors had said don’t look on the internet, but what do you do when you cannot sleep at 4am?

My searches unveiled the Melanoma Patients Australia Group and the support group operating at the time was incredible. I now carry on that legacy of support.

I researched online and found preliminary clinical trial results that looked promising. I called the pharmaceutical company MSD and found that I could enter a clinical trial at the Austin in Melbourne for the drug that is now called Keytruda. I live in Adelaide so involvement in this trial has required interstate travel every 2 weeks.

There were delays and more delays. I could feel tumours pop up around my ribs and on my collar bone and under my scalp. Sharp stabbing pains in my back and ribs made walking and sitting in certain positions very uncomfortable. I almost missed out on involvement in the trial due to the delays and my declining health.

A friend accompanied me to Melbourne for the ‘randomisation’. I was lucky enough to be placed in the group that was receiving the highest dose of the active drug, rather than the group receiving Yervoy (the standard treatment protocol which became available only in August of 2013). This wasa relief for me and my family given the financial and emotional investment they made for me to participate in the trial. Sue and I received the news whilst distracting ourselves in Melbourne central. We found a rooftop bar and ordered a glass each of bubbles – the first in 6 months! A month later I could feel the tumour on my collarbone shrink under my fingers.

The drug has worked and the result is magnificent. The first scan (three months after trial initiation) showed an incredible result. Since I started the trial 18 months ago, tumour shrinkage has been noted at all but two of my six-weekly scans (now 3 monthly). The trial is due to finish in October 2015. Although this drug has saved my life I am not clear of the disease. But my progression free survival has reached 18 months with no sign of abating.

If I had not been ‘pushy’ I would not have had access to this treatment. In my experience, patient experience varies largely depending on the treating hospital or doctor. For patients with advanced melanoma, time is not on their side, they need to be treated by an oncologist who is an expert in melanoma and is aware of and involved in trials for melanoma drugs.

Many fellow patients I have met on my journey have died because they were not as ‘lucky’ as I was: not lucky enough to have the ability to do their own research; not lucky enough to know when to move on to a new doctor; not lucky enough to be chosen in a random placement onto one of three arms in a trial; not lucky enough to have a family willing to make sacrifices to fly them to Melbourne fortnightly for treatment.

I have managed to return to work one day a week and am grateful for the support of my employer, Business SA, friends (who provide me with an ‘airport shuttle service’ as my flights and other transport costs are not covered by the trial) and colleagues. I have been lucky to also have a loving husband, three children and a magnificent mother who have supported me through this journey.

Because I have been luckier than most in my situation I have also taken on the role of SA facilitator for Melanoma Patients Australia: educating the public on risks of Australia’s national cancer; and supporting and being an advocate for other melanoma patients. We meet on the last Monday of every month at the Cancer Care Centre in Unley at 10.30am. My email is karen@vangorp.id.au, I am happy to speak to fellow melanoma sufferers and their carers either by email or phone and I encourage you to attend our get-togethers.

I have hope new treatments will see an end to this disease and that the Australian Government will expedite access to these drugs for all melanoma patients.

Scroll to Top

Privacy Policy

Australian Melanoma Research Foundation (AMRF) respects and is committed to protecting the privacy of the people whose personal information it collects. We collect personal information about individuals who are employed by us, our donors, our volunteers, other supporters, allied associations, consultants and service providers.

Information we collect

Whenever we collect personal information, we will identify ourselves as AMRF and ensure people are aware of why we are collecting information and how we plan to use it.

The type of personal information AMRF usually collects and holds includes names, addresses, telephone numbers, email addresses, donation date, reason for donation, merchandise orders and other information such as health related information pertaining to AMRF research and program delivery. This information may be collected in person, via our website on the secure payment gateway, as well as other sources.

When people visit our website, or download information from it, the following information is recorded by Google Analytics:

  • Their network location and IP address
  • The date and time of their visit, pages visited, and time spent on each page
  • Referring site details (ie the site and page they came from to arrive at this site)
  • Type of web browser they used
  • Type of operating system they used
  • JavaScript support, screen resolution, and screen colour processing ability

This information is only used for statistical and website development purposes. We make limited use of cookies on our website. We use cookies to improve the functionality of our website, and to remember user preferences when people return.

In the event where an individual shares unsolicited personal information that AMRF would not have collected for the purposes outlined above that information will be destroyed or de-identified as soon as is practicable.

How we use and disclose personal information

We collect and use stakeholder’s personal information to carry out the functions and activities of AMRF and to comply with our legal obligations, to maintain and update our records and to help us manage and provide our services.

We may also use information to ask for support and to keep people informed about the ways in which our donors and supporters help us to make a difference to raise funds for research, awareness and early detection programs.  People have the right to opt out of any communications from AMRF.  This will not stop them receiving receipts and other transactional communications as required by law.

We may disclose personal information to third parties who assist us to perform functions on our behalf (such as commercial mail preparation services, this information is permanently deleted by the provider upon completion of the service and confirmed in writing of such).  These external service providers are under a duty to maintain the privacy and security of your information in line with this Privacy Policy and to use your personal information only for the purpose for which it is disclosed.

AMRF does not use any government related identifiers, such as Medicare numbers or tax file numbers, of an individual as our own identifier.

Marketing and communications

We may use people’s information within AMRF only in connection with marketing and fundraising campaigns. We may provide marketing communications to stakeholders on an ongoing basis by telephone, electronic messages (eg. email), online (including websites and mobile apps) and other means, unless they opt out or we are subject to legal restrictions. These may include communications relating to AMRF and our programs, campaign and promotional messages, event invitations, fundraising opportunities and newsletters.

AMRF also sends transactional communications which include but are not limited to: Donation & Tax Receipts, forgotten password e-mails, event sign up confirmation and confirmations from Web forms.

To opt-out of receiving AMRF marketing communications people can:

  • Select the “unsubscribe” option in one of the marketing communications that they receive from us.
  • Send an email to: admin@melanomaresearch.com.au
  • Call us on 0419 822 969
  • Send a written request to: PO Box 574, Kent Town DC SA 5071

Security of personal information

AMRF regards the security of personal information as a priority and takes a number of precautions to protect people’s personal information from loss, misuse, unauthorised access, modification or disclosure. Specific security precautions are in place for processing online payments through payment gateway providers Stripe and PayPal which include the use of encrypted links, dedicated private connections and Secure Sockets Layer (SSL) encryption. However, the Internet is not a secure environment and although all care is taken, we cannot guarantee the security of information people provide to us via electronic means such as email.

If people become aware of any inaccuracy in the personal information, we hold about themselves, they are encouraged to contact AMRF so we can update any personal information we hold.


Where it is lawful and practicable, we will allow individuals to deal with us on an anonymous basis. For example, if we receive a telephone enquiry, we will not require that the enquirer gives us their name, although depending on the nature of the enquiry, we may not be able to answer it unless they do.

We can also accept gifts and other forms of support anonymously. However, provisions contained in taxation legislation require AMRF to collect the name of the donor if the donor requires a tax-deductible receipt.

Image copyright

AMRF’s reputation and goodwill is extremely important. Permission to use images featured on this website has only been given to AMRF and therefore should not be downloaded or used in any way by a third party without consent.

For information on obtaining permission for an image, please email admin@melanomaresearch.com.au.

Acceptance of terms

If AMRF updates or changes this Privacy Policy, the changes will be made on this page. Your continued use of AMRF’s website following the posting of changes will mean you accept those changes.

Contact us

If you have any questions about privacy-related issues OR you wish to lodge a complaint about a breach of this policy OR other privacy matter OR you do not wish to be contacted by us to ask for your support, please contact us by email at  admin@melanomaresearch.com.au. Alternatively our postal address is below:

PO Box 574
Kent Town DC SA 5071

We take your privacy concerns seriously. Where you express any concerns that we have interfered with your privacy, we will respond to let you know who will be handling your matter and when you can expect a further response. We may request additional details from you regarding your concerns and may need to engage or consult with other parties in order to investigate and deal with your issue. We will keep records of your request and any resolution.

For information about privacy generally, or if your concerns are not resolved to your satisfaction, you may contact the Office of the Australian Information Commissioner at www.oaic.gov.au and on 1300 363 992.